FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2998875844> ?p ?o ?g. }

• W2998875844 endingPage "613" @default.
• W2998875844 startingPage "603" @default.
• W2998875844 abstract "This study investigated the clinical outcomes and safety of apatinib mesylate in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in patients who progressed after standard therapy, and analyzed the kinase insert domain receptor (KDR) gene polymorphism.A total of 135 patients with advanced non-squamous NSCLC who received apatinib mesylate were included. Objective response rates were evaluated. Subsequently, progression-free survival (PFS) and overall survival (OS) were assessed and safety data were recorded. Additionally, peripheral blood and biopsy cancer tissue specimens were collected from the patients with NSCLC for the genotyping of the genetic polymorphism and mRNA expression of the KDR gene, respectively. Analysis on the association between genotypes and prognosis was conducted.The objective response rate of the 135 patients with NSCLC was 18.52%, disease control rate was 65.19%, median PFS was 3.95 months, and median OS was 10.05 months. Regarding the KDR gene polymorphism analysis, the distribution of the 4397T>C polymorphism genotypes was in accordance with the Hardy-Weinberg Equilibrium (P=0.868). Moreover, the prognosis analysis indicated that the median PFS of patients with the CC/TC and TT genotypes was 2.80 and 4.80 months, respectively (P=0.002). Furthermore, the median OS of patients with the two genotypes was 9.10 and 10.56 months, respectively (P=0.041). The multivariate Cox regression analysis showed that the TC/CC genotypes were an independent factor for PFS (odds ratio: 1.72, P=0.009). There was no correlation between the polymorphism and adverse reactions. Additionally, the mRNA expression analysis suggested that the mRNA levels of KDR in cancer tissues were significantly different between the TT and TC/CC genotypes (P<0.001).The clinical outcomes of treatment with apatinib mesylate for advanced non-squamous NSCLC in patients who progressed after standard therapy may be influenced by the KDR 4397T>C polymorphism through mediation of the mRNA expression of KDR." @default.
• W2998875844 created "2020-01-23" @default.
• W2998875844 creator A5015224182 @default.
• W2998875844 creator A5025589606 @default.
• W2998875844 creator A5028537926 @default.
• W2998875844 creator A5054388025 @default.
• W2998875844 creator A5057518416 @default.
• W2998875844 creator A5069028088 @default.
• W2998875844 date "2020-01-01" @default.
• W2998875844 modified "2023-10-16" @default.
• W2998875844 title "<p>Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the <em>KDR</em> Gene Polymorphism</p>" @default.
• W2998875844 cites W2014433798 @default.
• W2998875844 cites W2019607817 @default.
• W2998875844 cites W2128153851 @default.
• W2998875844 cites W2135140316 @default.
• W2998875844 cites W2145835533 @default.
• W2998875844 cites W2179853997 @default.
• W2998875844 cites W2272984102 @default.
• W2998875844 cites W2276228008 @default.
• W2998875844 cites W2568006712 @default.
• W2998875844 cites W2571501394 @default.
• W2998875844 cites W2745743726 @default.
• W2998875844 cites W2751140959 @default.
• W2998875844 cites W2772833994 @default.
• W2998875844 cites W2776252578 @default.
• W2998875844 cites W2793587264 @default.
• W2998875844 cites W2810957851 @default.
• W2998875844 cites W2883906054 @default.
• W2998875844 cites W2885503610 @default.
• W2998875844 cites W2888017322 @default.
• W2998875844 cites W2889646458 @default.
• W2998875844 cites W2891948540 @default.
• W2998875844 cites W2895942511 @default.
• W2998875844 cites W2900071893 @default.
• W2998875844 cites W2904481169 @default.
• W2998875844 cites W2909096337 @default.
• W2998875844 cites W2909393055 @default.
• W2998875844 cites W2910971690 @default.
• W2998875844 cites W2911931027 @default.
• W2998875844 cites W2914232380 @default.
• W2998875844 cites W2916209536 @default.
• W2998875844 cites W2916656667 @default.
• W2998875844 cites W2918846838 @default.
• W2998875844 cites W2920799158 @default.
• W2998875844 cites W2921589532 @default.
• W2998875844 cites W2937901763 @default.
• W2998875844 cites W2938071357 @default.
• W2998875844 cites W2939239354 @default.
• W2998875844 cites W2945302198 @default.
• W2998875844 cites W2995984529 @default.
• W2998875844 cites W310438974 @default.
• W2998875844 cites W4252639183 @default.
• W2998875844 doi "https://doi.org/10.2147/ott.s222985" @default.
• W2998875844 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6982468" @default.
• W2998875844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32021302" @default.
• W2998875844 hasPublicationYear "2020" @default.
• W2998875844 type Work @default.
• W2998875844 sameAs 2998875844 @default.
• W2998875844 citedByCount "14" @default.
• W2998875844 countsByYear W29988758442020 @default.
• W2998875844 countsByYear W29988758442021 @default.
• W2998875844 countsByYear W29988758442022 @default.
• W2998875844 countsByYear W29988758442023 @default.
• W2998875844 crossrefType "journal-article" @default.
• W2998875844 hasAuthorship W2998875844A5015224182 @default.
• W2998875844 hasAuthorship W2998875844A5025589606 @default.
• W2998875844 hasAuthorship W2998875844A5028537926 @default.
• W2998875844 hasAuthorship W2998875844A5054388025 @default.
• W2998875844 hasAuthorship W2998875844A5057518416 @default.
• W2998875844 hasAuthorship W2998875844A5069028088 @default.
• W2998875844 hasBestOaLocation W29988758441 @default.
• W2998875844 hasConcept C104317684 @default.
• W2998875844 hasConcept C121608353 @default.
• W2998875844 hasConcept C126322002 @default.
• W2998875844 hasConcept C135763542 @default.
• W2998875844 hasConcept C143998085 @default.
• W2998875844 hasConcept C156957248 @default.
• W2998875844 hasConcept C178790620 @default.
• W2998875844 hasConcept C185592680 @default.
• W2998875844 hasConcept C2776256026 @default.
• W2998875844 hasConcept C2780194963 @default.
• W2998875844 hasConcept C2780668389 @default.
• W2998875844 hasConcept C31467283 @default.
• W2998875844 hasConcept C55493867 @default.
• W2998875844 hasConcept C71924100 @default.
• W2998875844 hasConcept C86803240 @default.
• W2998875844 hasConcept C90924648 @default.
• W2998875844 hasConceptScore W2998875844C104317684 @default.
• W2998875844 hasConceptScore W2998875844C121608353 @default.
• W2998875844 hasConceptScore W2998875844C126322002 @default.
• W2998875844 hasConceptScore W2998875844C135763542 @default.
• W2998875844 hasConceptScore W2998875844C143998085 @default.
• W2998875844 hasConceptScore W2998875844C156957248 @default.
• W2998875844 hasConceptScore W2998875844C178790620 @default.
• W2998875844 hasConceptScore W2998875844C185592680 @default.
• W2998875844 hasConceptScore W2998875844C2776256026 @default.
• W2998875844 hasConceptScore W2998875844C2780194963 @default.
• W2998875844 hasConceptScore W2998875844C2780668389 @default.

• next